Modality
Nanobody
MOA
VEGFi
Target
MALT1
Pathway
PD-1/PD-L1
PAH
Development Pipeline
Preclinical
~Nov 2021
→ ~Feb 2023
Phase 1
~May 2023
→ ~Aug 2024
Phase 2
Nov 2024
→ Apr 2026
Phase 2Current
NCT05018302
1,229 pts·PAH
2024-11→2026-04·Active
1,229 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-04-172w awayPh2 Data· PAH
Trial Timeline
2025Q2Q3Q42026Q2
P2
Active
Catalysts
Ph2 Data
2026-04-17 · 2w away
PAH
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05018302 | Phase 2 | PAH | Active | 1229 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| BMY-7975 | Bristol-Myers Squibb | Phase 1 | MALT1 | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| GSK-6516 | GSK | Phase 1/2 | MALT1 | |
| VRT-6833 | Vertex Pharma | Preclinical | ALK | |
| BII-5240 | Biogen | Phase 2/3 | MALT1 | |
| ALN-3958 | Alnylam | Phase 2 | MALT1 | |
| Cevisacituzumab | Alnylam | Preclinical | MALT1 |